Summary & Overview
HCPCS J2515: Pentobarbital Sodium Injection, 50 mg
HCPCS Level II code J2515 represents a 50 mg unit of pentobarbital sodium injection, a short-acting barbiturate used for sedation, anesthetic induction, and seizure control in acute care settings. Nationally, accurate coding for parenteral controlled substances like pentobarbital is important for patient safety, regulatory compliance, and billing transparency because these agents are tightly regulated and used in high-acuity services.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical role of pentobarbital, typical sites of service where J2515 is billed, common billing modifiers, and the payers that commonly process claims for this code. The publication also highlights benchmarks and policy-relevant considerations affecting coverage and payment for injectable sedative and anticonvulsant therapies.
This summary provides practical context for coding staff, revenue cycle professionals, and clinical managers seeking to understand where J2515 fits within drug administration billing and payer interactions, along with pointers to areas where policy updates may affect reimbursement and clinical documentation.
Billing Code Overview
HCPCS Level II code J2515 denotes an injection of pentobarbital sodium, billed per 50 mg unit. The service represents administration of a short-acting barbiturate medication primarily used for sedation, induction of anesthesia, or control of refractory seizures, depending on clinical context.
-
Service type: Parenteral drug administration (injectable medication)
-
Typical site of service: Hospital inpatient and outpatient settings, surgical centers, emergency departments, and other clinical settings where intravenous or intramuscular sedation or anticonvulsant therapy is delivered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J2515 (injection, pentobarbital sodium, per 50 mg) is an adult inpatient or outpatient in a controlled procedural setting requiring deep sedation or short-duration general anesthesia for procedures such as palliative sedation, termination of life-sustaining measures in accordance with law and institutional policy, or rare procedural sedation when other agents are contraindicated. The clinical workflow begins with clinician assessment of indications, allergies, and concurrent medications, informed consent and documentation of goals of care where applicable. Pharmacy prepares the weight‑based dose in a secure medication area; nursing verifies dose and administers intravenous pentobarbital under direct physician supervision. Vital signs and level of consciousness are monitored continuously during administration and in the immediate recovery period. Documentation includes drug name, strength, total mg administered, route, time, supervising provider, and any sedation-related complications. Typical sites of service include inpatient hospital units, hospice inpatient units, ambulatory procedural suites, or designated end‑of‑life care areas where controlled substance handling and monitoring are available.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Clinical service provided by the physician as the primary service | When the reporting clinician is the primary provider administering or ordering the drug |